echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer and Ferring have reached a collaboration on degarelix acetate for prostate cancer drug injection

    Pfizer and Ferring have reached a collaboration on degarelix acetate for prostate cancer drug injection

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 17, Pfizer and Ferring formally announced that the two parties have reached a cooperation agreement on Ferring’s authorization of Pfizer to exclusively be responsible for the commercial operation of degarelix acetate (brand name: Feimenger®), an innovative drug for the treatment of prostate cancer, in mainland China.


    Degarelix Acetate for Injection is a drug developed by Ferring to treat prostate cancer.


    As China's aging problem continues to deepen, the incidence of prostate cancer is on the rise


    Note: The original text has been deleted

    Reference

    [1] Klotz et al (2008) The efficacy and safety of Degarelix: a 12month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.


    [2] Shi Xiaolei, Zhou Tie, Li Song, Sun Yinghao.


    [3] Prostate Cancer Group, Professional Committee of Urinary and Male Reproductive System Tumors, Chinese Anti-Cancer Association.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.